UK markets closed

NVO Dec 2024 115.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.9200-0.7300 (-15.70%)
As of 11:02AM EDT. Market open.
Full screen
Loading interactive chart…
  • Insider Monkey

    Novo Nordisk A/S (NVO): The Most Profitable Stock of the Last 20 Years According to Analysts?

    We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other profitable stocks. The stock market has a long history of generating wealth for investors. While past performance doesn’t guarantee […]

  • Benzinga

    Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval

    On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition. Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss. Related: Chinese Generic O

  • Investor's Business Daily

    Is Eli Lilly Stock A Sell On A Rare Stumble In Obesity Treatment?

    Is Eli Lilly stock a buy after shares have leveraged a comeback following the acquisition of Morphic and positive weight-loss drug news?